Integrin alpha 4 beta 1

Integrin alpha 4 beta 1 Molekülinformation

Englischer Name	Integrin alpha-4/beta-1	Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	6	Target-Alias	Integrin alpha4beta1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Integrin alpha-4/beta-1
Target-Alias	Integrin alpha4beta1
Anzahl der inverkehr gebrachten Arzneimittel	3
Anzahl der klinischen Arzneimittel	6
Höchste Forschungs- und Entwicklungsphase	Approved

Integrin alpha 4 beta 1 Produktliste

Attribut
Protein (2)Kits (1)
Produktbibliothek
Online (2)In Forschung (1)
Spezies
Human (3)
Etikett
His Tag (1)His Tag & Avi Tag (1)- (1)
Marker
Unconjugated (1)Biotin-labeled (1)- (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
FRT-P049	Human	-	Human Integrin α4β1 / VCAM-1 Inhibitor Screening Kit (TR-FRET)	Vorbestellung
IT1-H52W1	Human	HEK293	Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His Tag&Tag Free, low endotoxin	In den Warenkorb legen
IT1-H82W1	Human	HEK293	Biotinylated Human Integrin alpha 4 beta 1 (ITGA4&ITGB1) Heterodimer Protein, His,Avitag™&Tag Free	In den Warenkorb legen

Gesamtmenge3

Integrin alpha 4 beta 1 Molekülhintergrund

Integrins are transmembrane proteins that mediate interactions between adhesion molecules on adjacent cells and/or the extracellular matrix (ECM). Integrins have diverse roles in several biological processes including cell migration during development and wound healing, cell differentiation, and apoptosis. Their activities can also regulate the metastatic and invasive potential of tumor cells. Integrin alpha 4 beta 1(Alpha-4/beta-1) is receptors for fibronectin. Integrin alpha-4/beta-1 is a receptor for VCAM1 and recognizes the sequence Q-I-D-S in VCAM1.

Integrin alpha 4 beta 1 Molekülalias

Integrin alpha 4 beta 1,ITGA4&ITGB1

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Natalizumab biosimilar (GENERIUM Pharmaceuticals)	GNR-093	Phase 3 Clinical	Generium Pharmaceuticals	Multiple Sclerosis	Details
Avicursen	TV-1102; ATL/TV-1102; ATL-1102; ISIS-107248	Phase 2 Clinical	Ionis Pharmaceuticals Inc	Multiple Sclerosis; Muscular Dystrophy, Duchenne	Details
Alintegimod	7HP349; 7-HP-349; 7HP-349	Phase 2 Clinical	7 Hills Pharma LLC	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis	Details
LLP2A alendronate		Phase 1 Clinical	University Of California	Bone Diseases; Bone Diseases, Metabolic; Osteonecrosis; Osteoporosis	Details
ABBV-243	ABBV-243	Phase 1 Clinical	Abbvie Inc		Details
RBx-7796	RBx-7796	Clinical	Sun Pharmaceutical Industries Ltd	Asthma; Rhinitis, Allergic	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Carotegrast methyl	AJM-300	Approved	Ea Pharma, Eisai Co Ltd	Carogra	Japan	Colitis, Ulcerative	Ea Pharma Co Ltd	2022-03-28	Colitis, Ulcerative	Details
Natalizumab biosimilar (Polpharma Biologics)	PB-006; DST-356A1	Approved	Polpharma Biologics Sa	Tyruko	United States	Multiple Sclerosis; Crohn Disease	Sandoz Inc	2023-08-24	Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting	Details
Natalizumab	BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E	Approved	Biogen Inc, Perrigo Llc	Tysabri, Antegran, Antegren	United States	Crohn Disease; Multiple Sclerosis	Biogen Idec	2004-11-23	Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body	Details